The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

4.00

Estimated average

burden

hours per

response:

1. Issuer's Identity

CIK (Filer ID Number)

Previous X None

Entity Type

0001029142

Name of Issuer

DYNAVAX TECHNOLOGIES CORP

Jurisdiction of Incorporation/Organization

DELAWARE

X Corporation

Limited Partnership

Limited Liability Company

General Partnership Business Trust Other (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

DYNAVAX TECHNOLOGIES CORP

Street Address 1 Street Address 2

2929 SEVENTH STREET SUITE 100

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

BERKELEY CA 94710 5108485100

3. Related Persons

Last Name First Name Middle Name

Dina, M.D. Dino

Street Address 1 Street Address 2

c/o Dynavax Technologies

Corporation

2929 Seventh Street, Suite 100

City State/Province/Country ZIP/PostalCode

Berkeley CA 94710

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

President and Chief Executive Officer

Last Name First Name Middle Name

Coffman, Ph.D. Robert L.

Street Address 1 Street Address 2

c/o Dynavax Technologies

Corporation

2929 Seventh Street, Suite 100

City State/Province/Country ZIP/PostalCode

Berkeley CA 94710

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Vice President and Chief Scientific Officer

Last Name First Name Middle Name

Janowicz, Ph.D. Zbigniew

> **Street Address 1 Street Address 2**

c/o Dynavax Technologies

2929 Seventh Street, Suite 100 Corporation

ZIP/PostalCode City State/Province/Country

CA 94710 Berkelev

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe)

Last Name First Name Middle Name

Ostrach Michael S.

> **Street Address 1 Street Address 2**

c/o Dynavax Technologies

2929 Seventh Street, Suite 100 Corporation

> State/Province/Country ZIP/PostalCode City

CA Berkeley 94710

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Vice President, Chief Business Officer and General Counsel

Last Name First Name Middle Name

Jennifer Lew

> **Street Address 1 Street Address 2**

c/o Dynavax Technologies 2929 Seventh Street, Suite 100 Corporation

ZIP/PostalCode City **State/Province/Country**

Berkeley CA 94710

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Vice President, Finance

Last Name First Name Middle Name

Oronsky, Ph.D. Arnold

> **Street Address 2 Street Address 1**

c/o Dynavax Technologies 2929 Seventh Street, Suite 100 Corporation

> City State/Province/Country ZIP/PostalCode

Berkeley CA 94710

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Chairman of the Board of Directors

Last Name	First Name	Middle Name	
Buc	Nancy	L.	

Street Address 1 Street Address 2 c/o Dynavax Technologies

2929 Seventh Street, Suite 100

Corporation

Berkeley

Corporation

City State/Province/Country

> CA94710

ZIP/PostalCode

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Member of the Board of Directors

Middle Name Last Name First Name

Cano, Ph.D. Francis R.

> **Street Address 2 Street Address 1**

c/o Dynavax Technologies

2929 Seventh Street, Suite 100

ZIP/PostalCode City State/Province/Country

CA Berkeley 94710

Executive Officer X Director Promoter **Relationship:**

Clarification of Response (if Necessary):

Member of the Board of Directors

Last Name First Name Middle Name

Carson, M.D. Dennis

> **Street Address 2 Street Address 1**

c/o Dynavax Technologies

2929 Seventh Street, Suite 100 Corporation

> City State/Province/Country ZIP/PostalCode

Berkeley CA 94710

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Member of the Board of Directors

Last Name First Name Middle Name

Gilbert, Ph.D. M. Denise

Street Address 1 Street Address 2

c/o Dynavax Technologies 2929 Seventh Street, Suite 100

Corporation

ZIP/PostalCode City State/Province/Country

Berkeley CA 94710

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Member of the Board of Directors

Last Name First Name Middle Name

Kessel Mark

> **Street Address 1 Street Address 2**

c/o Dynavax Technologies 2929 Seventh Street, Suite 100

Corporation

City **State/Province/Country**

ZIP/PostalCode

CA Berkeley 94710

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Member of the Board of Directors

Last Name First Name Middle Name Lawrence, M.D. David M. **Street Address 2 Street Address 1** c/o Dynavax Technologies 2929 Seventh Street, Suite 100 Corporation State/Province/Country ZIP/PostalCode City CA 94710 Berkeley Executive Officer X Director Promoter **Relationship:** Clarification of Response (if Necessary): Member of the Board of Directors **Last Name First Name** Middle Name **Philips** Peggy V. **Street Address 1 Street Address 2** c/o Dynavax Technologies 2929 Seventh Street, Suite 100 Corporation City State/Province/Country ZIP/PostalCode Berkeley CA 94710 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): Member of the Board of Directors **Last Name First Name** Middle Name Plotkin, M.D. Stanley A. **Street Address 1 Street Address 2** c/o Dynavax Technologies 2929 Seventh Street, Suite 100 Corporation ZIP/PostalCode City State/Province/Country CA 94710 Berkeley **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): Member of the Board of Directors 4. Industry Group Agriculture Health Care Retailing Banking & Financial Services X Biotechnology Restaurants Commercial Banking Health Insurance Technology Insurance Hospitals & Physicians Computers **Investing** Pharmaceuticals Telecommunications **Investment Banking** Pooled Investment Fund Other Health Care Other Technology Is the issuer registered as Manufacturing Travel an investment company under Real Estate Airlines & Airports the Investment Company Commercial Act of 1940? **Lodging & Conventions** Construction No Yes Tourism & Travel Services Other Banking & Financial Services **REITS & Finance** Other Travel **Business Services** Residential Other Energy Other Real Estate Coal Mining **Electric Utilities**

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000)	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
X \$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)			
	Section 3(c)(1)	Section 3(c)(9)	
	Section 3(c)(2)	Section 3(c)(10)	
	Section 3(c)(3)	Section 3(c)(11)	
	Section 3(c)(4)	Section 3(c)(12)	
	Section 3(c)(5)	Section 3(c)(13)	
	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		

7. Type of Filing

X New Notice Date of First Sale 2009-12-30 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity Pooled Investment Fund Interests
X Debt Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities

X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)

Shares of Common Stock, Warrants to Purchase Common Stock and Convertible Promissory Note.

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Clarification of Response (if Necessary):
Acquisition of Symphony Dynamo, Inc.

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient CRD Number X None

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD X None

Number

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply) Check "All Statesâ€∏ or check individual

All States

Foreign/non-US

States

13. Offering and Sales Amounts

Total Offering Amount \$38,947,480 USD or Indefinite

Total Amount Sold \$20,067,480 USD

Total Remaining to be Sold \$18,880,000 USD or Indefinite

Clarification of Response (if Necessary):

Total Remaining to be Sold includes warrants and a promissory note that have been issued in this transaction. The aggregate exercise price of the warrants is \$3,880,000 and the convertible promissory note is in the amount of \$15,000,000.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
DYNAVAX TECHNOLOGIES	/s/ Michael S.	Michael S.	Vice President, Chief Business Officer and	2010-01-
CORP	Ostrach	Ostrach	General Counsel	06

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.